Longboard Pharma gains on FDA designations for lead asset

JHVEPhoto Longboard Pharmaceuticals ( NASDAQ: LBPH ) traded higher on Thursday after the U.S. FDA granted its Rare Pediatric Disease designation and Orphan Drug designation for the company’s lead candidate, bexicaserin, for its development work related to Dravet syndrome, a form of epilepsy.

The.